Literature DB >> 21874565

CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis.

Peng Xu1, Xiao-Lan Xu, Qiang Huang, Zhi-Hong Zhang, Yan-Bei Zhang.   

Abstract

Cancerous inhibitor of protein phosphatase 2A (CIP2A) and survivin are aberrantly expressed in a wide range of human cancers, including lung tumors. In order to assess the expressions of these two proteins in Chinese non-small-cell lung cancer (NSCLC) patients and determine their correlation with prognosis, NSCLC tissues and adjacent non-cancerous normal lung tissues were collected from 97 patients undergoing surgical treatment and evaluated by immunohistochemistry staining. CIP2A or survivin immunoreactivity was detected in significantly more NSCLC tissues than in adjacent non-cancerous lung tissues (P < 0.05). Moreover, CIP2A expression in NSCLC correlated with TNM stage, while survivin expression correlated with TNM stage and lymph node metastasis. Kaplan-Meier survival analysis showed that the overall survival times in patients expressing either CIP2A or survivin protein in NSCLC were shorter. COX regression analysis indicated that expression of CIP2A protein was an independent prognostic factor for NSCLC patients (HR = 3.631, P = 0.015). Therefore, CIP2A expression in Chinese NSCLC patients may be a useful biomarker of biological malignancy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21874565     DOI: 10.1007/s12032-011-0053-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  14 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Multidisciplinary management of lung cancer.

Authors:  Alexander Spira; David S Ettinger
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

3.  The role of CIP2A in oral squamous cell carcinoma.

Authors:  John R Basile; Rakefet Czerninski
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

Review 4.  The molecular basis and potential role of survivin in cancer diagnosis and therapy.

Authors:  D C Altieri
Journal:  Trends Mol Med       Date:  2001-12       Impact factor: 11.951

5.  CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.

Authors:  Qian-Ze Dong; Yang Wang; Xin-Jun Dong; Zi-Xuan Li; Zhong-Ping Tang; Quan-Ze Cui; En-Hua Wang
Journal:  Ann Surg Oncol       Date:  2010-09-15       Impact factor: 5.344

6.  Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.

Authors:  Kunio Okamoto; Isamu Okamoto; Wataru Okamoto; Kaoru Tanaka; Ken Takezawa; Kiyoko Kuwata; Haruka Yamaguchi; Kazuto Nishio; Kazuhiko Nakagawa
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

7.  CIP2A expression is increased in prostate cancer.

Authors:  Markku H Vaarala; Marja-Riitta Väisänen; Ari Ristimäki
Journal:  J Exp Clin Cancer Res       Date:  2010-10-21

8.  MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

Authors:  Anchit Khanna; Camilla Böckelman; Annabrita Hemmes; Melissa R Junttila; Jan-Patrik Wiksten; Mikael Lundin; Siina Junnila; Daniel J Murphy; Gerard I Evan; Caj Haglund; Jukka Westermarck; Ari Ristimäki
Journal:  J Natl Cancer Inst       Date:  2009-05-26       Impact factor: 13.506

9.  Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer.

Authors:  Linda Soo Hoo; Jianying Y Zhang; Edward K L Chan
Journal:  Oncogene       Date:  2002-07-25       Impact factor: 9.867

10.  CIP2A inhibits PP2A in human malignancies.

Authors:  Melissa R Junttila; Pietri Puustinen; Minna Niemelä; Raija Ahola; Hugh Arnold; Trine Böttzauw; Risto Ala-aho; Christina Nielsen; Johanna Ivaska; Yoichi Taya; Shi-Long Lu; Shujun Lin; Edward K L Chan; Xiao-Jing Wang; Reidar Grènman; Juergen Kast; Tuula Kallunki; Rosalie Sears; Veli-Matti Kähäri; Jukka Westermarck
Journal:  Cell       Date:  2007-07-13       Impact factor: 41.582

View more
  20 in total

1.  Clinical implications of CIP2A protein expression in breast cancer.

Authors:  Guangzhe Yu; Guohong Liu; Juan Dong; Yingyu Jin
Journal:  Med Oncol       Date:  2013-03-08       Impact factor: 3.064

Review 2.  Protein phosphatase 2A: a target for anticancer therapy.

Authors:  Danilo Perrotti; Paolo Neviani
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

3.  Ethoxysanguinarine Induces Inhibitory Effects and Downregulates CIP2A in Lung Cancer Cells.

Authors:  Zi Liu; Liang Ma; Zhe-Sheng Wen; Yong-Xian Cheng; Guang-Biao Zhou
Journal:  ACS Med Chem Lett       Date:  2013-12-20       Impact factor: 4.345

4.  Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies.

Authors:  Li-Nian Huang; Dong-Sheng Wang; Yu-Qing Chen; Cheng-Ling Zhao; Bei-Lei Gong; An-Bang Jiang; Wei Jia; Feng-Dan Hu
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

5.  Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.

Authors:  Yao-Kuang Wu; Chun-Yao Huang; Mei-Chen Yang; Chou-Chin Lan; Chih-Hsin Lee; Err-Cheng Chan; Kuei-Tien Chen
Journal:  Med Oncol       Date:  2014-06-25       Impact factor: 3.064

6.  CIP2A expression and prognostic role in patients with esophageal adenocarcinoma.

Authors:  Tuomo Rantanen; Tuuli Kauttu; Jonne Åkerla; Teemu Honkanen; Leena Krogerus; Jarmo Salo; Timo Paavonen; Niku Oksala
Journal:  Med Oncol       Date:  2013-08-08       Impact factor: 3.064

7.  Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.

Authors:  Danica D Wiredja; Marzieh Ayati; Sahar Mazhar; Jaya Sangodkar; Sean Maxwell; Daniela Schlatzer; Goutham Narla; Mehmet Koyutürk; Mark R Chance
Journal:  Proteomics       Date:  2017-10-25       Impact factor: 3.984

8.  CIP2A is a target of bortezomib in human triple negative breast cancer cells.

Authors:  Ling-Ming Tseng; Chun-Yu Liu; Kung-Chi Chang; Pei-Yi Chu; Chung-Wai Shiau; Kuen-Feng Chen
Journal:  Breast Cancer Res       Date:  2012-04-26       Impact factor: 6.466

9.  CircTMC5 promotes gastric cancer progression and metastasis by targeting miR-361-3p/RABL6.

Authors:  Peng Xu; XiaoLan Xu; Xiao Wu; LiXiang Zhang; Lei Meng; ZhangMing Chen; WenXiu Han; Jie Yao; AMan Xu
Journal:  Gastric Cancer       Date:  2021-07-22       Impact factor: 7.370

10.  Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.

Authors:  Ting-Ting Chao; Cheng-Yi Wang; Yen-Lin Chen; Chih-Cheng Lai; Fang-Yu Chang; Yi-Ting Tsai; Chung-Hao H Chao; Chung-Wai Shiau; Yuh-Chin T Huang; Chong-Jen Yu; Kuen-Feng Chen
Journal:  Oncotarget       Date:  2015-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.